H1 results and market reaction
Shares of SKAN climbed 6.8% to CHF 61.6 following the Allschwil-based maker of isolator and cleanroom systems releasing its H1 2026 interim results. Investors reacted to a wide-ranging beat that covered revenue, profitability and ordering activity.
Financial performance
Net revenue for the period rose 22.2% year-over-year to CHF 164.5 million, or 24.0% on a currency-adjusted basis. The company moved from a net loss of CHF 8.3 million in H1 2025 to a net profit of CHF 5.4 million in H1 2026, producing earnings per share of CHF 0.21.
EBITDA increased substantially, climbing from CHF 0.9 million in H1 2025 to CHF 15.3 million in the latest period. Operating cash flow registered CHF 16.3 million.
Drivers of the turnaround
Management attributed the swing to profitability to several factors: there were far fewer project delays compared with the prior-year period; a larger share of projects progressed into their higher-margin, value-added execution phases; and SKAN benefitted from the first full-period contributions of the Metronik and ABC Transfer acquisitions.
The Services & Consumables segment showed especially strong momentum, with order intake increasing by more than 54%, indicating growing traction in recurring, higher-margin revenue streams.
Orders and backlog
Order intake across the company rose 16.3% to CHF 247.6 million. The order backlog expanded 27.8% to CHF 442.3 million, a development the company linked to robust demand from pharmaceutical and biotech customers, with particular strength noted in the United States.
Regulatory milestone and guidance
Management confirmed it remains on track to secure Swissmedic regulatory approval later this year for its "Pre-Approved Services" offering, which SKAN intends to establish as a third core business pillar. The company also reiterated full-year 2026 guidance, forecasting net sales growth in the high-teens and an EBITDA margin in the 13% to 15% range.
Market context and valuation signals
The broader market provided no tailwind on the day, with U.S. equities broadly lower, but SKAN's combination of returning profitability, a growing order backlog and a clear confirmation of guidance created a strong near-term catalyst for the stock. The shares remain below their 52-week high of CHF 70.6 and have recovered from a 52-week low of CHF 35.75, suggesting investors see the H1 performance as evidence that the company's operational recovery is progressing.
Conclusion
SKAN's H1 2026 figures show a multi-faceted improvement: revenue growth, a shift back to net profitability, stronger EBITDA and a larger order book. Management's reaffirmed guidance and the pending Swissmedic approval for the Pre-Approved Services initiative were central to the market's positive reception.